A Phase II, Randomised, Double-blind, Placebo-controlled Study of MT-3995 in Subjects With Diabetic Nephropathy
Phase of Trial: Phase II
Latest Information Update: 29 Jan 2015
Price : $35 *
At a glance
- Drugs Apararenone (Primary)
- Indications Diabetic nephropathies
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Mitsubishi Tanabe Pharma Corporation
- 26 Jan 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 18 Aug 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 12 Feb 2014 Planned number of patients changed from 30 to 45 according to ClinicalTrials.gov record.